Inactive Instrument

Pardes Biosciences, Inc.

Equities

PRDS

US69945Q1058

Biotechnology & Medical Research

Pardes Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 08:06 am EDT

Pardes Biosciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 27.64 million compared to USD 8.14 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 3.45 a year ago.
For the six months, net loss was USD 49.08 million compared to USD 12.66 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 8.17 a year ago.

Latest news about Pardes Biosciences, Inc.

Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from S&P TMI Index	23-09-05	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from NASDAQ Composite Index	23-08-31	CI
MediPacific, Inc. completed the acquisition of Pardes Biosciences, Inc. from a group of shareholders.	23-08-30	CI
Pardes Biosciences Receives Tender Offer for MediPacific Merger Deal	23-08-28	MT
Pardes Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
North American Morning Briefing : Earnings -2-	23-07-19	DJ
Pardes Biosciences Agrees to Be Acquired by MediPacific; Shares Rise	23-07-17	MT
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 2500 Value Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell Small Cap Comp Value Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 2000 Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 3000 Value Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell Small Cap Completeness Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 2000 Value Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 2000 Dynamic Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 2500 Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 3000 Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 3000E Value Index	23-06-23	CI
Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 3000E Index	23-06-23	CI
Pardes Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Pardes Biosciences, Inc. Announces Termination of Brian P. Kearney as Chief Development Office, Effective May 15, 2023	23-04-21	CI
SVB Securities Downgrades Pardes Biosciences to Market Perform From Outperform, Lowers Price Target to $2 From $9	23-04-04	MT
Jefferies Downgrades Pardes Biosciences to Hold From Buy, Lowers Price Target to $1.25 From $10	23-04-03	MT
Pardes Biosciences to suspend COVID-19 drug development after mid-stage trial fails	23-04-03	RE
Pardes Biosciences to suspend COVID-19 drug development after mid-stage trial fails	23-04-03	RE
Pardes Biosciences Board Initiates Review of Strategic Alternative	23-04-03	CI

Chart Pardes Biosciences, Inc.

Duration

Period

More charts

Company Profile

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. Its lead product candidate, pomotrelvir, which targets the coronavirus disease (COVID-19). Pomotrelvir is in clinical development to treat COVID-19 in adult and pediatric patients. The Company, by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, it has discovered and is developing novel product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. Its lead product candidate, pomotrelvir, inhibits the main coronaviral cysteine protease (Mpro), a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. Inhibiting Mpro prevents the liberation and assembly of the viral replication complex, blocking replication before it begins.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+47.58%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research